Teva Lifts Sales View as Brand-Name Business Gains Traction

Dow Jones07-29

Teva Pharmaceutical Industries raised its sales outlook after its brand-name products logged higher revenue growth in the second quarter.

The drug maker swung to a second-quarter loss of $576 million, or 49 cents a share, from a profit of $282 million, or 24 cents a share, a year earlier.

Stripping out certain one-time items, adjusted per-share earnings were 2 cents, behind the 5 cents anticipated by analysts, according to FactSet. Adjusted earnings includes a 61-cent reduction from the acquisition of Emalex, which closed in June.

Second-quarter revenue fell about 1% to $4.14 billion. Analysts surveyed by FactSet forecast revenue of $3.97 billion.

Sales from generic drugs fell 15%, mainly due to lower revenues from lenalidomide capsules in the U.S. The capsules are a generic version of Revlimid, an oral drug for treating blood cancers, which faced increased generic competition in the U.S. during the quarter, Teva said.

Teva, which has historically focused on generic drugs, is also trying to grow its brand-name business. Its three brand-name products collectively grew 43% to $1 billion in revenue.

Teva raised its annual sales outlook to a range of $16.5 billion to $16.85 billion, up from $16.4 billion to $16.8 billion. It maintained guidance for adjusted earnings.

Shares rose 4% to $32.91 in premarket trading.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655675268?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655675268","market":"nz","top_or_hot":-1,"title":"Teva Lifts Sales View as Brand-Name Business Gains Traction","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries raised its sales outlook after its brand-name products logged higher revenue growth in the second quarter. \n</p>\n<p>\n  The drug maker swung to a second-quarter loss of $576 million, or 49 cents a share, from a profit of $282 million, or 24 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, adjusted per-share earnings were 2 cents, behind the 5 cents anticipated by analysts, according to FactSet. Adjusted earnings includes a 61-cent reduction from the acquisition of Emalex, which closed in June. \n</p>\n<p>\n  Second-quarter revenue fell about 1% to $4.14 billion. Analysts surveyed by FactSet forecast revenue of $3.97 billion. \n</p>\n<p>\n  Sales from generic drugs fell 15%, mainly due to lower revenues from lenalidomide capsules in the U.S. The capsules are a generic version of Revlimid, an oral drug for treating blood cancers, which faced increased generic competition in the U.S. during the quarter, Teva said. \n</p>\n<p>\n  Teva, which has historically focused on generic drugs, is also trying to grow its brand-name business. Its three brand-name products collectively grew 43% to $1 billion in revenue. \n</p>\n<p>\n  Teva raised its annual sales outlook to a range of $16.5 billion to $16.85 billion, up from $16.4 billion to $16.8 billion. It maintained guidance for adjusted earnings. \n</p>\n<p>\n  Shares rose 4% to $32.91 in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Lifts Sales View as Brand-Name Business Gains Traction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Lifts Sales View as Brand-Name Business Gains Traction\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-29 19:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries raised its sales outlook after its brand-name products logged higher revenue growth in the second quarter. \n</p>\n<p>\n  The drug maker swung to a second-quarter loss of $576 million, or 49 cents a share, from a profit of $282 million, or 24 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, adjusted per-share earnings were 2 cents, behind the 5 cents anticipated by analysts, according to FactSet. Adjusted earnings includes a 61-cent reduction from the acquisition of Emalex, which closed in June. \n</p>\n<p>\n  Second-quarter revenue fell about 1% to $4.14 billion. Analysts surveyed by FactSet forecast revenue of $3.97 billion. \n</p>\n<p>\n  Sales from generic drugs fell 15%, mainly due to lower revenues from lenalidomide capsules in the U.S. The capsules are a generic version of Revlimid, an oral drug for treating blood cancers, which faced increased generic competition in the U.S. during the quarter, Teva said. \n</p>\n<p>\n  Teva, which has historically focused on generic drugs, is also trying to grow its brand-name business. Its three brand-name products collectively grew 43% to $1 billion in revenue. \n</p>\n<p>\n  Teva raised its annual sales outlook to a range of $16.5 billion to $16.85 billion, up from $16.4 billion to $16.8 billion. It maintained guidance for adjusted earnings. \n</p>\n<p>\n  Shares rose 4% to $32.91 in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2655675268","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655675268","pubTimestamp":1785325500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Teva Pharmaceutical Industries raised its sales outlook after its brand-name products logged higher revenue growth in the second quarter.The drug maker swung to a second-quarter loss of $576 million, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","TEVA":"梯瓦制药","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4007":"制药","BK4559":"巴菲特持仓","BK4588":"碎股","BK4596":"哈里斯概念","BK4566":"资本集团","BK4584":"避孕概念","BK4585":"ETF&股票定投概念"},"translate_title":"随着品牌业务获得牵引力，梯瓦提升销售前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":0.9},"content_text":"Teva Pharmaceutical Industries raised its sales outlook after its brand-name products logged higher revenue growth in the second quarter. \n\n\n  The drug maker swung to a second-quarter loss of $576 million, or 49 cents a share, from a profit of $282 million, or 24 cents a share, a year earlier. \n\n\n  Stripping out certain one-time items, adjusted per-share earnings were 2 cents, behind the 5 cents anticipated by analysts, according to FactSet. Adjusted earnings includes a 61-cent reduction from the acquisition of Emalex, which closed in June. \n\n\n  Second-quarter revenue fell about 1% to $4.14 billion. Analysts surveyed by FactSet forecast revenue of $3.97 billion. \n\n\n  Sales from generic drugs fell 15%, mainly due to lower revenues from lenalidomide capsules in the U.S. The capsules are a generic version of Revlimid, an oral drug for treating blood cancers, which faced increased generic competition in the U.S. during the quarter, Teva said. \n\n\n  Teva, which has historically focused on generic drugs, is also trying to grow its brand-name business. Its three brand-name products collectively grew 43% to $1 billion in revenue. \n\n\n  Teva raised its annual sales outlook to a range of $16.5 billion to $16.85 billion, up from $16.4 billion to $16.8 billion. It maintained guidance for adjusted earnings. \n\n\n  Shares rose 4% to $32.91 in premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655675268","isCrawlerRequest":true}